La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Tactile Systems Tech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Tactile Systems Tech..

Tactile Systems Tech (NASDAQ:TCMD) Azioni, Catena delle Opzioni

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is entering a pivotal week, as concerns over a potentially overheating U.S. economy continue to drag down <a href="https://www.benzinga.com/money/bitcoin-price-prediction">the apex cryptocurrency</a>.
What Happened: Following a stronger-than-expected <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">non-farm payrolls report</a>, which showed 256,000 jobs added against a forecast of 164,000, fears of accelerated inflation have been reignited, leading to a retreat in equity markets, according to QCP Capital.
The robust employment data has effectively nullified expectations of <a href="https://www.benzinga.com/content/42932732/with-this-kind-of-data-the-fed-isnt-cutting-rates-this-year">near-term interest rate cuts</a> by the Federal Reserve.
Compounding these concerns are the prospects of potential <a href="https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms">Trump-era tariffs</a>, which could further escalate inflationary pressures.
Bitcoin is trading around $91,100 in early morning U.S. hours, down 3.4% over the past 24 hours. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has followed king crypto lower, trading around $3,080, 5.8% down. 
Key economic data releases, including the Producer Price Index (PPI), Consumer Price Index (CPI) and Unemployment Claims are all scheduled for this week. 
Any further signs of an overheating economy could further test the markets, posing a challenge to the narrative that crypto is a safe haven against inflation.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42921493/cryptos-capitol-hill-breakthrough-senate-subcommittee-signals-shifting-political-winds">Crypto&#8217;s Capitol Hill Breakthrough: Senate Subcommittee Signals Shifting Political Winds</a>
Why It Matters: In addition to economic uncertainties, the crypto industry is also seeing significant political developments, President-elect Donald Trump is reportedly forming a cryptocurrency advisory council, comprised of around 24 CEOs and founders, including major figures from industry giants like MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), <a href="https://www.bloomberg.com/news/articles/2025-01-09/crypto-ceos-fly-to-mar-a-lago-make-large-donations-as-inauguration-day-nears?embedded-checkout=true">according</a> to Bloomberg.
This council aims to provide guidance on digital asset policy and help draft legislation with Congress. 
The advisors will also work with government agencies, with an aim to establish a <a href="https://www.benzinga.com/25/01/42779917/trump-wont-announce-strategic-bitcoin-reserve-via-executive-order-says-analyst-he-would-likely-buy-btc-in-the-background">strategic Bitcoin reserve</a>.
Crypto.com CEO Kris Marszalek, as well as MicroStrategy executive chairman Michael Saylor, have <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42785039/michael-saylor-meets-eric-trump-says-bitcoin-is-on-the-menu-at-mar-a-lago">visited Mar-a-Lago</a> to discuss policies and potential roles within the incoming administration.
Coinbase CEO Brian Armstrong and Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) CEO Brad Garlinghouse have also reportedly met with Trump recently to offer their support. 
Circle CEO Jeremy Allaire recently stated that his firm donated 1 million (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) to Trump&#8217;s inaugural committee.
The formation of this council, along with the significant involvement of industry leaders, signifies a potential shift toward a more crypto-friendly regulatory environment in the U.S, while simultaneously placing the spotlight on crypto&#8217;s relevance in times of economic uncertainty. 
This week's developments could prove to be a major inflection point for digital assets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42909925/previewing-todays-most-important-jobs-report-what-it-means-for-bitcoin">Previewing Today&#8217;s &#8216;Most Important Jobs Report&#8217; — What It Means For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

$USDC

$XRP

COIN

MSTR

Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data

Wallbox Receives U.S. UL Certification For Quasar 2 Bidirectional Charger

Evercore ISI Group analyst David Raso upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Underperform to In-Line and announces $365 price target.

Upgrades

Price Target

Analyst Ratings

Evercore ISI Group Upgrades Caterpillar to In-Line, Announces $365 Price Target

The Company will report fourth quarter and fiscal year 2024 financial results on February 25, 2025, and will provide detailed results and 2025 guidance at that time.
The Company also expects full year 2024 adjusted operating margin to be at the high end of the previous guidance range of 10.5–11.0%.&nbsp;
In addition, Amer Sports announced that it has repaid all $1.2 billion of its outstanding term loans in the fourth quarter and expects fiscal year 2025 adjusted net finance costs to approximate $120 million, as compared to the previous guidance of $180-190 million.

Guidance

Amer Sports Expects FY24 Revenue Growth To Be At High End Of Prior Guidance Range Of 16 – 17% Despite Currency Headwinds In Q4

Biotech

Earnings

Health Care

General

MDGL

Madrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra

On a Preliminary Basis, for the Fourth Quarter (13-weeks ended December 31, 2024), the Company expects:
<ul>
<li>Total revenues in the range of $211 million to $216 million, an increase from its previous guidance of $210 million to $215 million and representing growth of 10% at the mid-point of the range from fourth quarter fiscal 2023 total revenues of $194.8 million; and</li>
<li>Adjusted EBITDA in the range of $25.5 million to $27.5 million, an increase from its previous guidance of $25 million to $27 million and representing growth of 13% at the mid-point of the range from fourth quarter fiscal 2023 adjusted EBITDA of $23.4 million.</li>
</ul>
On a Preliminary Basis, for the Fiscal Year 2024 (52-weeks ended December 31, 2024), the Company expects:
<ul>
<li>Total revenues in the range of $889 million to $894 million, an increase from its previous guidance of $888 million to $893 million and representing growth of 12% at the mid-point of the range from total revenues of $794 million in fiscal year 2023; and</li>
<li>Adjusted EBITDA in the range of $110.5 million to $112.5 million, an increase from its previous guidance of $110 million to $112 million and representing growth of 25% at the mid-point of the range from Adjusted EBITDA of $89.2 million in fiscal year 2023.</li>
</ul>
The Company is introducing Fiscal Year 2025 Guidance (52-weeks ending December 31, 2025) and expects:
<ul>
<li>Total revenues in the range of $950 million to $970 million; and</li>
<li>Adjusted EBITDA in the range of $115 million to $125 million.</li>
</ul>

OneSpaWorld Expects Q4 Revenue Of $211M-$216M (Prior $210M-$215M) Vs $213.9M Est, FY24 Revenue Of $889M-$894M (Prior $888M-$893M) Vs $891.7M Est, FY25 Revenue Of $950M-$970M Vs $968.97M Est

<ul>
<li>Strategy prioritizes most accelerated path to first potential approval&nbsp;</li>
<li>Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data anticipated in the first half of 2025</li>
<li>Topline pivotal data for neladalkib (NVL-655) in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025</li>
</ul>

NUVL

Nuvalent Targets 2026 Approval With Accelerated NDA For Zidesamtinib In ROS1-Positive NSCLC

USFD

US Foods Holding Reaffirms Previously Announced FY24 Guidance For Net Sales Of $37.7B - $38.0B  (Est $37.878B), Adjusted EPS Of $3.05 - $3.15 (Est $3.12)

a.k.a. Brands Announces New Leadership: Ciaran Long As CEO, Kevin Grant As CFO

AIRS

AirSculpt Technologies Expects 2024 Revenues Of Approximately $180M Compared To Previous Guidance Of $183M-$189M And Consensus Of $185.601M, With Adjusted EBITDA Of ~$20.5M Compared To Prior Guidance Of $23M-$28M

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Forestar Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>)</h3>
<ul>
<li>On Jan. 6, Citigroup analyst Anthony Pettinari maintained Forestar Group with a Buy and lowered the price target from $43 to $39. The company' stock fell around 10% over the past month and has a <a href="https://www.benzinga.com/quote/FOR">52-week low of $24.81</a>.</li>
<li>RSI Value: 20.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>FOR Price Action: Shares of Forestar Group fell 2.5% to close at $25.10 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">latest FOR news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69.png" alt="" class="wp-image-730282" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064401/image-69-768x726.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<h3 class="wp-block-heading">American Assets Trust, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAT#NYSE">AAT</a>)</h3>
<ul>
<li>American Assets Trust will announce its fourth quarter and year-end 2024 earnings after the market closes on Tuesday, Feb. 4. The company's stock fell around 10% over the past five days and <a href="https://www.benzinga.com/quote/AAT">has a 52-week low</a> of $20.03.</li>
<li>RSI Value: 22.7</li>
<li>AAT Price Action: Shares of American Assets Trust fell 3.2% to close at $23.56 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">trend in AAT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70.png" alt="" class="wp-image-730284" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064428/image-70-768x705.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Alexander&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>)</h3>
<ul>
<li>On Nov. 4, Alexander&#8217;s posted better-than-expected quarterly results. The company's stock fell around 12% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ALX">low of $185.00.</a></li>
<li>RSI Value: 25.9</li>
<li>ALX Price Action: Shares of Alexander&#8217;s fell 6.6% to close at $186.88 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">breakout in ALX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="880" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71.png" alt="" class="wp-image-730285" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71.png 880w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13064521/image-71-768x730.png 768w" sizes="(max-width: 880px) 100vw, 880px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

Top 3 Real Estate Stocks That May Rocket Higher This Quarter

B of A Securities analyst Chase Mulvehill downgrades Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) from Buy to Neutral and maintains the price target from $22.5 to $22.5.

Downgrades

AESI

B of A Securities Downgrades Atlas Energy Solutions to Neutral, Maintains Price Target to $22.5

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) with a Buy and maintains $19 price target.

Reiteration

ARQT

HC Wainwright & Co. Reiterates Buy on Arcutis Biotherapeutics, Maintains $19 Price Target

The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) and Fosfatados Centro SPE Ltda (‘Fosfatados Centro') announced today that they have entered into an agreement for the sale of a phosphate asset owned by Mosaic located in Patos de Minas, Brazil. Upon the closing of the transaction, Fosfatados Centro will assume responsibility for the Patos de Minas mine and tailings dams and pay Mosaic $125 million (USD) in cash over six years. The transaction is subject to regulatory approvals, including approval by the Brazilian Administrative Council for Economic Defense (CADE), and other conditions precedents.

Asset Sales

Mosaic Sells Brazilian Phosphate Asset to Fosfatados Centro for $125M, Pending Regulatory Approval

<ul>
<li>Net Sales Increased 6.8% Compared to the Fourth Quarter of 2023, with U.S. Net Sales up 21.6%</li>
<li>Raised Adjusted EBITDA1 Guidance to be Between $6.0 million and $6.2 Million in the Fourth Quarter</li>
</ul>

Small Business

a.k.a. Brands Reports Preliminary 2024 Revenue Of $574.7M (+5.2% YoY), And Q4 $159M (+6.8% YoY); Expects Adjusted EBITDA Between $23M-$23.2M For 2024

SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXWW#NASDAQ">SMXWW</a>) (the "Company"), today announced that the reverse stock split of the Company's ordinary shares, which was previously approved by the Company's shareholders on December 10, 2024, will begin trading on an adjusted basis giving effect to the reverse stock split on January 15, 2025 under the existing ticker symbol "SMX". The new CUSIP number of the Company's ordinary shares will be G8267K 158 and the new ISIN code will be IE000WZ90ZV5.
In accordance with the proposal approved by the Company's shareholders and the Board of Directors' subsequent determination to fix the split ratio at 28.5:1, every twenty-eight and one-half (28.5) ordinary shares of the Company will be automatically combined into one (1) ordinary share. This will reduce the number of outstanding ordinary shares of the Company from approximately 33 million to approximately 1 million.

Stock Split

SMXWW

SMX Announces 28.5:1 Reverse Stock Split, Adjusted Trading to Begin January 15, 2025

HC Wainwright &amp; Co. analyst Heiko Ihle maintains NioCorp Developments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) with a Buy and lowers the price target from $8.5 to $3.25.

HC Wainwright & Co. Maintains Buy on NioCorp Developments, Lowers Price Target to $3.25

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearwateranalytics.com%2F%3Futm_medium%3Dthird-party%26utm_source%3Dpress-release%26utm_campaign%3Dbw-enfusion&amp;esheet=54178021&amp;newsitemid=20250113430675&amp;lan=en-US&amp;anchor=Clearwater+Analytics&amp;index=1&amp;md5=d504209e354f2352d1385093fd4f42bb">Clearwater Analytics</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) ("Clearwater") and Enfusion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service (SaaS) solutions for the investment management and hedge fund industry. The purchase price is $11.25 per share, delivered in an approximately equal mix of cash and stock. Additionally, Clearwater will pay $30 million to terminate Enfusion's tax receivable agreement (TRA). This equates to a purchase price of approximately $1.5 billion.

CWAN

ENFN

Clearwater Analytics to Acquire Enfusion for $1.5B in Cash and Stock Deal

SuperCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has secured a new electronic monitoring (EM) contract with a Juvenile Probation Agency in Ohio. This contract marks SuperCom's first project with a government agency in Ohio and its entry into its sixth new U.S. state since the summer of 2024, highlighting SuperCom's expansion momentum in providing innovative public safety solutions nationwide. This contract also marks the 20th new EM contract in the U.S. since the summer of 2024.
&nbsp;
The project in Ohio will include SuperCom's innovative PureOne technology, which provides real-time GPS tracking, secure communication, and advanced compliance capabilities. The discreet PureOne device, designed with a humane approach, helps participants avoid stigma while remaining integrated into society and continuing their rehabilitation journey. These cutting-edge solutions are tailored specifically for correctional and juvenile programs, enhancing public safety while promoting reintegration and operational efficiency.

SPCB

SuperCom Expands to Ohio, Secures Juvenile Probation EM Contract with Innovative PureOne Technology

Needham analyst Scott Berg reiterates ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Buy and maintains $125 price target.

TTAN

Needham Reiterates Buy on ServiceTitan, Maintains $125 Price Target

Tactile Systems Technology GAAP EPS of $0.21 beats by $0.03, revenue of $73.09M misses by $2.92M

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology ( ($TCMD) ) has released its Q3 earnings. Here is a breakdown of the information Tactile Systems Technology presented to...

Tactile Systems Technology Reports Q3 2024 Results, Launches Share Buyback

BTIG downgraded Tactile Systems (TCMD) to Neutral from Buy without a price target following the Q3 report. While the shares are inexpensive and Tac...

Tactile Systems downgraded to Neutral from Buy at BTIG

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report), with a p...

Piper Sandler Sticks to Their Buy Rating for Tactile Systems Technology (TCMD)

Tactile Systems cut to Neutral at BTIG after Q3 revenue miss

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Boeing union to end strike, Palantir reports Q3 beat: Morning Buzz

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing patient care. Keep reading... The integration of AI in healthcare is continuously transforming the operations and processes of the medical field. Companies engaged in the healthcare industry are leveraging artificial intelligence (AI) to advance patients' care and lower costs propelling the medical technology market.
Given the industry's bright prospects, investors could consider investing in sound healthcare technology stocks Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>), which are revolutionizing patient care.
The healthcare industry is undergoing rapid transformation owing to the pandemic, shifting demographics, rapid technological advancements, and rising patient expectations. As a result, healthcare companies are increasingly investing in and <a href="https://mobidev.biz/blog/technology-trends-healthcare-digital-transformation">adapting digital technologies</a> to maintain their competitive edge and offer the best solutions to patients.
Concrete technologies like telemedicine, AI-enabled medical devices, and blockchain electronic health records are <a href="https://www.digitalauthority.me/resources/state-of-digital-transformation-healthcare/">entirely reshaping healthcare processes and operations</a>. These modernized technologies, along with offering operational capabilities, also help companies reduce their costs, enhance operational efficiency, and mitigate other risks.
Blockchain technologies, AI, and the Internet of Things (IoT) have significantly impacted the healthcare sector along with emerging devices and infrastructures that are helping doctors, healthcare organizations, and patients gain immediate access to healthcare information, resulting in better decision-making and treatment options.
Fortune Business Insights projects the global healthcare IT market to grow to $981.23 billion by 2032, <a href="https://www.fortunebusinessinsights.com/healthcare-it-market-109359">exhibiting a CAGR of 15.4%</a>, driven by healthcare information technology opportunities like improving clinical outcomes, reducing human error, improving practice efficiencies, and facilitating care coordination.
Given these favorable market trends, let's look at the fundamentals of the top three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks, starting with the third choice.
Stock #3: Zimmer Biomet Holdings, Inc. (<a href="https://stocknews.com/stock/ZBH/">ZBH</a>)
ZBH operates as a medical technology company globally. It designs, manufactures, and markets orthopedic reconstructive products, like knee and hip products, S.E.T. products, and craniomaxillofacial and thoracic products. It also offers robotic, surgical, and bone cement products.
On November 25, ZBH announced U.S. FDA Premarket Approval Application (PMA) supplement approval for the Oxford&#xAE; Cementless Partial Knee. The partial knee allows surgeons to perform a PKR with improved fixation, better long-term implant survival rate, and improved efficiency in the operating room compared to the Oxford cemented partial knee procedure.
The Oxford cementless partial knee is now the only FDA-approved cementless partial knee implant in the U.S. This marked a revolutionary step offering patients a better range of motion, a more natural feel, and a more stable implant-to-bone fixation.
Also, on November 18, ZBH received the CE Mark certification for its Persona&#xAE; revision knee system. The addition to the Persona segment instills ZBH's commitment to personalized solutions, offering surgeons advanced tools for revision knee arthroplasty.
For the third quarter of 2024, which ended September 30, ZBH's total revenues increased 4% year-over-year to $1.82 billion. The company's adjusted <a href="https://www.investopedia.com/terms/o/operating_profit.asp">operating profit</a> grew 3.5% from the year-ago value to $480.20 million. Adjusted net earnings of ZBH amounted to $353.20 million or $1.74 per common share, up 1.9% and 5.5% year-over-year, respectively.
In addition, the company's free cash flow rose 64.3% from the prior year's quarter to $310 million.
According to the company's updated guidance for fiscal 2024, ZBH projects reported revenue change between 3.5% and 4%. It also expects adjusted EPS in the $7.95 - $8.05 range.
Street expects ZBH's revenue and EPS for the fourth quarter (ending December 2024) to increase 3.9% and 4.3% year-over-year to $2.02 billion and $2.30, respectively. Moreover, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
ZBH's stock has increased 7.7% over the past month to close the last trading session at $112.02.
ZBH's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, ZBH is ranked #26 out of 138 stocks.
<a href="https://stocknews.com/stock/ZBH/">Click here</a> to access additional ratings of ZBH for Momentum, Sentiment, and Stability.
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE offers infection prevention products and services worldwide. The company operates in three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing systems and tracking products, endoscopy accessories, and other equipment.
On October 30, STE declared the distribution of a quarterly interim dividend of $0.57 per share. The dividend is to be paid on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.
With 14 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 1.06% at the current share price. Its four-year average dividend yield is 0.86%. And the company's dividend payouts have increased at a 9.5% CAGR over the past three years.
STE's total revenues increased 7.3% year-over-year to $1.33 billion for the third quarter that ended September 30, 2024. The company's gross profit grew 6% from the year-ago value to $578.79 million. Net income attributable to stockholders came in at $150.03 million and $1.51 per share, indicating growth of 30.1% and 30.2% year-over-year, respectively.
Analysts expect STE's revenue for the first quarter (ending June 2025) to grow 6.5% year-over-year to $1.36 billion. For the same quarter, its EPS is expected to increase 12.5% year-over-year to $2.28. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
STE's shares have gained 8% over the past year to close the last trading session at $217.47.
STE's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Sentiment. Within the Medical – Devices &amp; Equipment industry, STE is ranked #12 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have STE ratings for Value, Growth, Quality, and Momentum. Get all STE ratings <a href="https://stocknews.com/stock/STE/">here</a>.
Stock #1: Tactile Systems Technology, Inc. (<a href="https://stocknews.com/stock/TCMD/">TCMD</a>)
TCMD is a medical technology company that develops and provides medical devices to treat underserved chronic diseases. The company offers Flexitouch Plus system and Entre Plus System. It also has a mobile application, Kylee, which helps patients learn about lymphedema.
On October 2, TCMD launched Nimbl&#x2122;, its next-generation pneumatic compression platform for the treatment of upper extremity lymphedema. Nimbl is significantly smaller and lighter than previous device iterations and is indicated for treating patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing.
This important portfolio addition reflects TCMD's commitment to advancing solutions that increase patient access to therapy with a differentiated user experience.
TCMD reported total revenue of $73.09 million, up 5% year-over-year during the third quarter that ended June 30, 2024, and its non-GAAP gross profit grew 10.9% from the year-ago value to $55.10 million. The company's adjusted EBITDA of $10.72 million indicates a growth of 39.3% from the prior year's quarter.
Furthermore, the company's net income came in at $5.16 million and $0.21 per common share for the quarter, respectively.
Street expects TCMD's revenue for the second quarter (ending June 2025) to increase 9.2% year-over-year to $79.95 million, and its EPS for the same period is expected to grow 16.6% year-over-year to $0.23. Also, the company has topped the consensus EPS estimate in three of the trailing four quarters.
Shares of TCMD have surged 49.3% over the past six months and 34.9% over the past year to close the last trading session at $18.93.
TCMD's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
TCMD has an A grade for Value and a B for Quality. The stock is ranked #6 among the 138 stocks in the same industry.
In addition to the POWR Ratings we've stated above, we also have TCMD ratings for Growth, Sentiment, Momentum, and Stability. Get all TCMD ratings <a href="https://stocknews.com/stock/TCMD/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZBH shares were trading at $112.02 per share on Thursday morning, up $1.38 (+1.25%). Year-to-date, ZBH has declined -7.37%, versus a 27.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zbh-ste-tcmd-3-healthcare-technology-companies-revolutionizing-patient-care/>3 Healthcare Technology Companies Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Technology Companies Revolutionizing Patient Care

Virtual Meeting to be held on December 10 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Tactile Systems management to meet virtually with B. Riley

Tactile Systems Technology: A First Look

AAPL

ALAB

AZPN

BWIN

CRRFY

CVNA

DLTR

EBAY

EGHT

JELD

NFLX

NXPI

PAYO

PLTR

QNST

REAL

SLAB

TCMD

UBER

VMEO

Press Releases

Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results

Tactile Medical to Present at the William Blair 44th Annual Growth Stock Conference

Tactile Medical to Release Second Quarter of Fiscal Year 2024 Financial Results on August 5, 2024

Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results

Tactile Medical Receives PDAC Approval for Nimbl™ Lymphedema Platform

Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy

Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

Tactile Medical to Release Third Quarter of Fiscal Year 2024 Financial Results on November 4, 2024

Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results

Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference

Comments

Tactile Systems Tech

Tactile Systems Tech (TCMD) Opzioni

Tactile Systems Tech (NASDAQ:TCMD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO